Cherian K

Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.

11 papers · 9 preprints

ArticleIbogaine

Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol.

Geoly AD, Coetzee JP, Buchanan DM +16

ArticleIbogaine

Neural Correlates of Ibogaine: Evidence From Functional Neuroimaging of Military Veterans.

Sridhar M, Azeez A, Geoly AD +10

ArticleIbogaine

Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.

Olash C, Buchanan DM, Brown R +6

PreprintIbogaine

Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries

Rolle C, Williams N, Faerman A +15

Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).

Beutler BD, Shinozuka K, Tabaac BJ +5

ArticlePsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.

Tabaac BJ, Shinozuka K, Arenas A +5

ArticlePsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.

Tabaac BJ, Shinozuka K, Arenas A +5

ArticleKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine.

Evans VD, Arenas A, Shinozuka K +5

ArticleIbogaine

Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.

Cherian K, Shinozuka K, Tabaac BJ +5

ArticleKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics.

Muir OS, Shinozuka K, Beutler BD +5

Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA).

Shinozuka K, Tabaac BJ, Arenas A +5

ArticleAyahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians-N,N-Dimethyltryptamine and Ayahuasca.

Shinozuka K, Tabaac BJ, Arenas A +5

PreprintKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VII. Ketamine

Evans VD, Arenas A, Shinozuka K +5

PreprintKetamine

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VIII. The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Muir OS, Shinozuka K, Beutler BD +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VI. 3,4-methylenedioxy-methamphetamine (MDMA)

Shinozuka K, Tabaac BJ, Arenas A +5

PreprintPsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview

Tabaac BJ, Shinozuka K, Arenas A +5

PreprintIbogaine

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine

Cherian K, Shinozuka K, Tabaac BJ +5

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part II. Lysergic acid diethylamide (LSD)

Beutler BD, Shinozuka K, Tabaac BJ +5

PreprintPsilocybin

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part IV. Psilocybin

Tabaac BJ, Shinozuka K, Arenas A +5

PreprintAyahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part III. N,N-dimethyltryptamine (DMT) and Ayahuasca

Shinozuka K, Tabaac BJ, Arenas A +5